Imvax, Inc

Imvax is a clinical-stage biotechnology company developing personalized, whole tumor-derived immunotherapies. Imvaxs combination therapy uniquely captures the complete antigenic signature of a patients own tumor and converts it into a highly stimulatory training program for the patients immune system. The comprehensive nature of this training is intended to result in both innate and adaptive immune stimulation to optimize long-term anti-tumor effects. The companys lead program is in glioblastoma multiforme (GBM), an extremely aggressive form of brain cancer, with additional programs in other types of solid tumors

Immunotherapy,biotechnology,autologous vaccines,biopharmaceuticals,glioblastoma multiforme,clinical trials,and research

Imvax, inc operates in the Biotechnology research industry.

Imvax, inc's revenue is 11m - 100m

Imvax, inc has 11 - 50 employees.